Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3

United Therapeutics reported positive results from TETON-1, its second Phase III trial testing nebulised Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF). The trial, involving 598 patients over 52 weeks, showed that nebulised Tyvaso was superior to placebo in improving forced vital capacity (FVC) by 130.1 mL, and also achieved statistical significance in reducing the risk […]

Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3 Read Post »

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list

Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. She founded United Therapeutics in 1996, to make medicines for her daughter who suffered from pulmonary arterial hypertension, and is now developing genetically modified pig organs for human transplant. On the latter topic she has written a book titled “Your life or mine

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list Read Post »

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026

The PROSERA study for seralutinib in pulmonary arterial hypertension findings were released yesterday and report that it did not meet its primary endpoint in the full population. It appears that unexpected placebo results in some geographical areas may have been responsible for this happening. While this is disappointing news for the patient community the program

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026 Read Post »

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

TRANSLATE »
Scroll to Top